Expert System for Automatic Analysis of Data Quality in Clinical Trials

In the framework of the development scheme 'Central Innovation Scheme for Medium-sized Businesses' of the German Federal Ministry for Economics and Technology (BMWI), clinIT AG, based in Freiburg, Germany, has been awarded a six-figure federal grant in cooperation with the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems.

The IT company, clinIT, intends to develop a novel tool for automatic analysis of data quality in all types of clinical studies. Up to now, such analyses had to be carried out individually for each project via the application programming. On the basis of rules, this new tool will formalize this process and make automatic processing accessible.

For the first time now, this innovation will give project and data managers with no specific programming skills the means to measure and control the quality of data and processes over large-volume study libraries/data bases. The data quality is crucial in a clinical trial, in order to be able to reach accurate and reliable conclusions on the safety and efficacy of the test medication. The new development of clinIT and the Freiburg Institute for Informatics represents not only a decisive advance from the perspective of cost-effectiveness, but especially also in terms of the patient's well-being.

For further information, please visit:
http://www.clinit.net

About clinIT AG
Founded in 2001, clinIT AG is a specialist for clinical information technology whose core business is the development and supply of information systems for both data entry and management of clinical trial data as well as providing support for the process flow in clinical studies. The latter involves systems for data capture, patient randomization and disease management. Further services include statistics, data management and medical consulting. For more information, please visit www.clinit.net.

About the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems
The Institute for Informatics was founded in 1995 and belongs to the Faculty of Applied Sciences of the University. The Faculty for Data Bases and Information Systems has special expertise in the sector of rule-based languages, work flow management systems and internet-based technologies, especially information extraction and integration. Current research projects concern also memory systems for the semantic web and the analysis of correspondingly based query languages. For more information, please visit www.informatik.uni-freiburg.de/.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...